The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (OPD) - Immunodiagnostic Systems Hldgs PLC

24 May 2021 13:39

RNS Number : 6177Z
Immunodiagnostic Systems Hldgs PLC
24 May 2021
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Immunodiagnostic Systems Holdings plc

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Immunodiagnostic Systems Holdings plc

(d) Is the discloser the offeror or the offeree?

OFFEREE

(e) Date position held:

The latest practicable date prior to the disclosure

21 May 2021

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

NIL

0

NIL

0

(2) Cash-settled derivatives:

 

NIL

0

NIL

0

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

NIL

0

NIL

0

 

TOTAL:

NIL

0

NIL

0

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

a) Interests of directors of Immunodiagnostic Systems Holdings plc in Immunodiagnostic Systems Holdings plc's ordinary shares of 2 pence each

 

Name

Number of ordinary shares of 2 pence each

Percentage of total issued share capital (%) (excluding treasury shares and any shares held under option)

Klaus Peter Kaspar

18,100

0.06

Paul James Martin

22,350

0.08

Jaap Stuut

7,500

0.03

Peter John Williamson

45,000

0.16

Burkhard Wittek*

8,259,759

28.70

 

*Dr Wittek's shares are held by Forum Venture Capital GmbH, Forum European Smallcaps GmbH, Forum Family Office Venture Fund and his spouse and children

 

b) Details of awards granted to the directors of Immunodiagnostic Systems Holdings plc over Immunodiagnostic Systems Holdings plc's ordinary shares of 2 pence each

Name

Number of ordinary shares of 2 pence each

Percentage of total issued share capital (%) (excluding any shares held under option)

Grant date

Vesting date

Exercise price (p)

Expiry date

Jaap Stuut

7,500

0.03

29/03/18

29/03/21

220

29/03/28

Jaap Stuut

7,500

0.03

28/03/19

06/12/21

190

28/03/29

Jaap Stuut

7,500

0.03

31/03/20

20/02/23

210

31/03/30

Jaap Stuut

7,500

0.03

17/05/21

29/03/24

195

17/05/31

Paul Martin

30,000

0.10

28/03/17

23/06/19

132

28/03/27

Paul Martin

9,000

0.03

28/03/17

28/03/20

277.5

28/03/27

Paul Martin

6,300

0.02

29/03/18

20/06/20

290

29/03/28

Paul Martin

2,283

0.01

29/03/18

29/03/21

220

29/03/28

Paul Martin

3,717

0.01

29/03/18

29/03/21

220

29/03/28

Paul Martin

6,750

0.02

28/03/19

06/12/21

184

28/03/29

Paul Martin

30,000

0.10

25/06/19

23/06/22

180

25/06/29

Paul Martin

9,000

0.03

31/03/20

21/02/23

220

31/03/30

Paul Martin

9,000

0.03

31/03/20

23/03/23

170

31/03/30

Paul Martin

6,300

0.02

17/05/21

20/06/23

275

17/05/31

Paul Martin

6,000

0.02

17/05/21

29/03/24

195

17/05/31

 

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

24 May 2021

Contact name:

Paul Martin

Telephone number:

+44 ( 0) 191 519 6111

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FEEEAASLADXFEFA
Date   Source Headline
29th Oct 20077:00 amRNSNotice of Results
5th Oct 200712:11 pmRNSNotifiable Interest
2nd Oct 20077:01 amRNSSenior Management Appointment
17th Sep 20073:33 pmRNSNotifiable Interest
17th Sep 20077:01 amRNSBoard Appointment
10th Sep 20073:48 pmRNSNotifiable Interest
3rd Sep 20077:01 amRNSTotal Voting Rights
3rd Sep 20077:00 amRNSCompletion of Acquisition
31st Aug 20073:16 pmRNSAGM Statement
28th Aug 20071:48 pmRNSResult of EGM
20th Aug 200712:36 pmRNSNotifiable Interest
20th Aug 20079:53 amRNSAIM Rule 26
3rd Aug 20077:00 amRNSProposed Acquisition
31st Jul 200711:03 amRNSTotal Voting Rights
26th Jul 20077:01 amRNSCompletion of acquisition
16th Jul 20075:57 pmRNSCorrection re. dividend dates
16th Jul 20077:01 amRNSFinal Results
29th Jun 20077:01 amRNSNotice of Results
18th Jun 20077:02 amRNSImmunoassay kits agreement
8th May 20077:01 amRNSNotifiable Interest
3rd May 20073:39 pmRNSDirectors Dealing
21st Mar 20077:00 amRNSTrading Statement
20th Mar 20075:33 pmRNSNotifiable Interest
13th Mar 20077:00 amRNSBoard Appointment
12th Feb 20077:02 amRNSBoard Appointment
31st Jan 20077:02 amRNSProduct launch
4th Jan 20077:00 amRNSProduct Launch
21st Dec 200612:48 pmRNSTotal Voting Rights
5th Dec 20069:44 amRNSDirector/PDMR Shareholding
4th Dec 20067:02 amRNSAutomation agreement
15th Nov 20068:54 amRNSHolding(s) in Company
6th Nov 20067:01 amRNSInterim Results
19th Oct 200611:34 amRNSNotice of Results
10th Oct 20067:02 amRNSIDS launches into Austria
13th Sep 20067:00 amRNSLaunch of new assay kit
22nd Aug 200611:04 amRNSAGM Statement
17th Jul 20064:35 pmRNSHolding(s) in Company
5th Jul 20067:00 amRNSFinal Results
30th May 20067:03 amRNSMarketing & sales agreement
15th May 20067:01 amRNSDirectorate Change
12th Apr 20067:01 amRNSDirector/PDMR Shareholding
30th Mar 20067:01 amRNSPre-close Trading update
21st Feb 20062:38 pmRNSDirectors Dealing
7th Nov 20057:00 amRNSInterim Results
26th Oct 20059:52 amRNSNotice of Results
26th Sep 20057:01 amRNSBoard Appointment
6th Sep 200511:18 amRNSAGM Statement
12th Aug 200510:42 amRNSFDA Approval
12th Jul 20057:01 amRNSFinal Results
6th Jul 20053:19 pmRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.